Triple negative breast cancer (TNBC) is a heterogeneous disease with aggressive behavior
and poor prognosis. Genomic sequencing has detected a distinctive mutational portrait of …

Triple-negative breast cancer (TNBC) is associated with a poor prognosis and defines a
subgroup of patients who do not benefit from endocrine or anti-HER2 therapy. Rather than …

BRCA1 mutation carriers have a higher risk of developing triple-negative breast cancer
(TNBC), which is a refractory disease due to its non-responsiveness to current clinical …

To characterize the prevalence of BRCA mutations and characteristics of BRCA carriers in
China and to update the clinical recommendations for BRCA testing, we conducted a wide …

Cancer is often called a disease of aging. There are numerous ways in which cancer
epidemiology and behaviour change with the age of the patient. The molecular bases for …

The breast cancer susceptibility gene (BRCA) is an important tumor suppressor gene,
including BRCA1 and BRCA2, a biomarker that assesses the risk of breast cancer and …

Background: Platinum-based agents may benefit patients with triple-negative breast cancer
(TNBC) whose tumors are dysfunctional in DNA repair mechanisms associated with the …

PURPOSE The absolute cumulative risk of contralateral breast cancer (CBC) for patients
with BRCA1/2 variants is unknown. The purpose of this study was to develop a CBC risk …

Background: Expert consensus on BRCA1/2 genetic testing and clinical application in
Chinese breast cancer patients recommends that BRCA1/2 testing should be performed in …

Breast-conserving surgery (BCS) including radiotherapy (RT) has been demonstrated to
provide at least equivalent prognosis to mastectomy in early-stage breast cancer. However …